Last €48.10 EUR
Change Today 0.00 / 0.00%
Volume 0.0
LLY On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
Sao Paulo
EN Paris
Frankfurt
As of 9:56 AM 07/15/14 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Open
€48.10
Previous Close
€48.10
Day High
€48.10
Day Low
€48.10
52 Week High
07/15/14 - €48.10
52 Week Low
01/8/14 - €36.06
Market Cap
53.8B
Average Volume 10 Days
10.0
EPS TTM
--
Shares Outstanding
1.1B
EX-Date
08/13/14
P/E TM
--
Dividend
€1.96
Dividend Yield
3.02%
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency, as well as provides anti-infectives. Its neuroscience products treat major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and brain imaging of beta-amyloid neuritic plaques. The company’s oncology products treat pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as malignant pleural mesothelioma; and cardiovascular products are used to treat erectile dysfunction and benign prostatic hyperplasia, and pulmonary arterial hypertension, as well as to reduce thrombotic cardiovascular events and as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to enhance milk productivity in dairy cows; anticoccidial agents; and products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections. The company distributes its products through independent wholesale distributors and directly to pharmacies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

37,925 Employees
Last Reported Date: 02/19/14
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $680.7K
Senior Vice President and General Counsel
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2013.

eli lilly & co (LLY) Key Developments

Eli Lilly Announces to Cut 100 Jobs, Move Work Overseas

Eli Lilly and Co. announced that will send some drug production overseas and cut up to 100 Indianapolis jobs under a plan to "rebalance" its tablet and capsule manufacturing business. The expiration of patents on several Lilly drugs, which sent their sales plummeting, is part of the reason for the restructuring. As many as 100 positions will be affected by the moves. Employees in those jobs will be offered other jobs locally, including in the insulin and other biotech product lines. Lilly has committed to spending nearly $500 million on insulin facilities in Indianapolis, including cartridge-filling plants for the pen injection devices diabetics use.

Eli Lilly and Company Announces Non-Clinical Study Results from Alzheimer's Disease Study

Eli Lilly and Company has announced results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE, which found that combination therapy was more effective in removing clumps of amyloid-beta protein in the brain, a component that is thought to lead to Alzheimer's disease, or AD, than use of one therapy. The non-clinical study results showed that when used on their own (as monotherapies), the beta-secretase inhibitor and the N3pG beta-amyloid antibody removed approximately 50% of the clumps of amyloid-beta protein, whereas the combination therapy resulted in an even more substantial 86% removal. Additionally, combination therapy significantly lowered deposited Ab1-42 75% relative to the time zero controls. Histological analyses indicated that the BACE inhibitor monotherapy resulted in removal of diffuse deposits of beta-amyloid, the antibody monotherapy resulted in removal of cored plaques, and the combination therapy removed both the diffuse deposits and cored plaques. Multiple different types of biochemical analyses confirmed that the combination treatment was superior to the monotherapy treatments.

Anthera Pharmaceuticals, Inc. Enters into License Agreement with Eli Lilly and Company

Anthera Pharmaceuticals Inc. entered into a license agreement with Eli Lilly and Company, pursuant to which the company obtained an exclusive worldwide license to certain technology and compounds relating to a clinical stage pancreatic enzyme replacement therapy, Liprotamase. Under the agreement, the company obtained (i) exclusive rights to develop, make, have made, use, import, offer for sale and sell licensed compounds and pharmaceutical formulations thereof, including Liprotamase and (ii) certain rights to grant sublicenses. The licensed patent rights include a specific set of previously filed U.S. and foreign patents and applications, as well as any applications filed after the execution date by Lilly that relate to licensed know-how. Under the terms of the License Agreement, the company assumes sole control of and responsibility for all aspects of developing, obtaining regulatory approval for, and commercializing the licensed products in the covered territory. Under the terms of the license agreement, the company is obligated to make royalty and milestone payments and other payments to and on behalf of Lilly. Milestone payments are to be made as the licensed products receive regulatory approval.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:FP €48.10 EUR 0.00

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.89 USD -0.08
AbbVie Inc $54.08 USD -0.40
Amgen Inc $122.26 USD +0.25
Bristol-Myers Squibb Co $49.46 USD +0.14
Teva Pharmaceutical Industries Ltd $54.40 USD -0.65
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 18.0x
Price/Sales 3.1x
Price/Book 3.8x
Price/Cash Flow 18.6x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.